NUVL

Nuvalent, Inc. (NUVL) | Rumor.io

Nuvalent

NUVL

Attention (50-day avg)0%

Attention rank (50-day avg)#2,062

Bullish sentiment (50-day avg)92%

Price to earnings ratio-21.2

Market capitalization9.8B

Earnings per share-6.06

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-425.4M

Social

What share of all stock conversation is about NUVL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Jun 10

Nuvalent, Inc. ($NUVL) has been acquired by GlaxoSmithKline (GSK) for $10.6 billion in cash, with a price of $124 per share.
The acquisition is expected to close in Q3 2026, with Nuvalent's stock surging 39.3% to $123.25 on the news.
Analysts expect Nuvalent's drug therapies to reach peak annual sales of $4 billion, with the company's current valuation at $9.74 billion.

Generated by AI

Sentiment

Of the messages about NUVL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	88.63% +0.17
Bearish	—	—	—	11.37% -0.17

Bullish· Jun 9

Nuvalent, Inc. ($NUVL) has been acquired by GlaxoSmithKline ($GSK) for $10.6 billion, with Nuvalent's shares surging 39% in pre-market trading.
The acquisition values Nuvalent at $124 per share, a 40% premium, and gives GlaxoSmithKline two late-stage lung cancer candidates that could launch this year if approved.
This acquisition is a significant vote of confidence in Nuvalent's oncology-focused science, with GlaxoSmithKline citing the company's proven track record of developing better and safer cancer therapies.

Bearish· Jun 9

Nuvalent, Inc. (NUVL) has been acquired by GlaxoSmithKline (GSK) for $10.6 billion, accelerating GSK's oncology growth.
The deal is seen as a 40% premium to Nuvalent's previous close, but some analysts question whether the company's price was artificially lowered before the acquisition to make the premium look better.
Nuvalent's stock price was already down from $110 to $90 during negotiations, and some speculate that the company's value was intentionally dropped to make the acquisition look more attractive.

Generated by AI

Topics

Of the messages about NUVL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	65.16%
Technical Analysis	—	—	0%	3.82%
Analysts	—	—	33.33%	11.84%
Earnings	—	—	33.33%	9.02%
Macro	—	—	33.33%	10.02%
Controversies	—	—	0%	0.13%

Jun 9

GSK agreed to buy Nuvalent for $10.6 billion, valuing the company at $124 per share, a 40% premium to its last closing price.
The acquisition gives GSK two late-stage lung cancer drugs that could launch this year if approved, as part of the company's effort to rebuild its oncology franchise.
The deal is an all-cash transaction, with GSK paying $124 per share, and is expected to close in 3Q.

Generated by AI

Community

Of the messages about NUVL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	38.1%
Newcomers	—	—	100%	61.9%

Regulars· Nov 17

Nuvalent's Alkove-1 data shows a lower ORR (objective response rate) of 31% compared to the phase 1 stage, with details still to be delved into.
The company is set to release neladalkib data from the pivotal part of Alkove-1 in TKI pretreated ALK+ve NSCLC today at 6:30am ET.
Nuvalent's stock price has surged +10% despite concerns over waning data and liver tox worries, with the company pressing ahead in the ALK space.

Newcomers· Jun 10

Newcomers to the Nuvalent, Inc. (NUVL) asset are focused on the massive 39.3% surge in stock price, with one post highlighting a $10k investment at IPO now worth $68,094.
Many newcomers are discussing the recent acquisition of NUVL by GlaxoSmithKline (GSK) for $10.6 billion, with some expressing surprise at the high acquisition price and others discussing the implications for the biotech sector.
Newcomers are also analyzing the performance of NUVL stock, with one post highlighting a 580% return over 5 years and another noting that the stock had a SmartScore of 9/10 before the deal, indicating that hedge funds were quietly loading up on the stock.

Generated by AI

News

GSK secures first lung cancer approval, validating $10.6bn Nuvalent bet

Jideytro will now enter a lung cancer niche dominated by Pfizer’s Lorbrena.

2mo agoYahoo Finance

GSK Lands FDA Approval for Nuvalent-Acquired Jideytro for NSCLC

GSK secures early FDA approval for Jideytro, its first lung cancer therapy, backed by strong ARROS-1 data, and strengthens its precision oncology portfolio.

2mo agoYahoo Finance

Also Discussed

Investors talking about NUVL also mention

#	Name	Attention
1	Nuvation Bio Inc.NUVB	0%0
2	Janux Therapeutics, Inc.JANX	0%0
3	Vaxcyte Inc.PCVX	0%0
4	Revolution Medicines, Inc.RVMD	0.01%-0.01
5	Crinetics Pharmaceuticals IncCRNX	0%0
6	Structure Therapeutics Inc. American Depositary SharesGPCR	0%new
7	Immunovant Inc.IMVT	0%0
8	TERN - Terns Pharmaceuticals, Inc.	——
9	Replimune Group, Inc.REPL	0%0
10	ETNB - 89bio, Inc.	——

Nuvalent, Inc.

Healthcare
Biotechnology

Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on developing precisely targeted therapies for patients with cancer. The company applies structure-based drug design and chemistry expertise to create small-molecule treatments aimed at clinically proven kinase targets, with an emphasis on improving selectivity and addressing resistance mechanisms. Its current programs center on non-small cell lung cancer, including therapies for ROS1-positive and ALK-positive disease, as well as a HER2-altered program in early clinical development. Nuvalent’s work is positioned within the oncology sector, where it contributes to the development of targeted medicines intended to support more durable responses and better tolerability across patient populations.

Website

Location

One Broadway

Cambridge, MA, 02142

United States

Social

What share of all stock conversation is about NUVL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Jun 10

Nuvalent, Inc. ($NUVL) has been acquired by GlaxoSmithKline (GSK) for $10.6 billion in cash, with a price of $124 per share.
The acquisition is expected to close in Q3 2026, with Nuvalent's stock surging 39.3% to $123.25 on the news.
Analysts expect Nuvalent's drug therapies to reach peak annual sales of $4 billion, with the company's current valuation at $9.74 billion.

Generated by AI

Sentiment

Of the messages about NUVL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	88.63% +0.17
Bearish	—	—	—	11.37% -0.17

Bullish· Jun 9

Nuvalent, Inc. ($NUVL) has been acquired by GlaxoSmithKline ($GSK) for $10.6 billion, with Nuvalent's shares surging 39% in pre-market trading.
The acquisition values Nuvalent at $124 per share, a 40% premium, and gives GlaxoSmithKline two late-stage lung cancer candidates that could launch this year if approved.
This acquisition is a significant vote of confidence in Nuvalent's oncology-focused science, with GlaxoSmithKline citing the company's proven track record of developing better and safer cancer therapies.

Bearish· Jun 9

Nuvalent, Inc. (NUVL) has been acquired by GlaxoSmithKline (GSK) for $10.6 billion, accelerating GSK's oncology growth.
The deal is seen as a 40% premium to Nuvalent's previous close, but some analysts question whether the company's price was artificially lowered before the acquisition to make the premium look better.
Nuvalent's stock price was already down from $110 to $90 during negotiations, and some speculate that the company's value was intentionally dropped to make the acquisition look more attractive.

Generated by AI

Topics

Of the messages about NUVL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	65.16%
Technical Analysis	—	—	0%	3.82%
Analysts	—	—	33.33%	11.84%
Earnings	—	—	33.33%	9.02%
Macro	—	—	33.33%	10.02%
Controversies	—	—	0%	0.13%

Jun 9

GSK agreed to buy Nuvalent for $10.6 billion, valuing the company at $124 per share, a 40% premium to its last closing price.
The acquisition gives GSK two late-stage lung cancer drugs that could launch this year if approved, as part of the company's effort to rebuild its oncology franchise.
The deal is an all-cash transaction, with GSK paying $124 per share, and is expected to close in 3Q.

Generated by AI

Community

Of the messages about NUVL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	38.1%
Newcomers	—	—	100%	61.9%

Regulars· Nov 17

Nuvalent's Alkove-1 data shows a lower ORR (objective response rate) of 31% compared to the phase 1 stage, with details still to be delved into.
The company is set to release neladalkib data from the pivotal part of Alkove-1 in TKI pretreated ALK+ve NSCLC today at 6:30am ET.
Nuvalent's stock price has surged +10% despite concerns over waning data and liver tox worries, with the company pressing ahead in the ALK space.

Newcomers· Jun 10

Newcomers to the Nuvalent, Inc. (NUVL) asset are focused on the massive 39.3% surge in stock price, with one post highlighting a $10k investment at IPO now worth $68,094.
Many newcomers are discussing the recent acquisition of NUVL by GlaxoSmithKline (GSK) for $10.6 billion, with some expressing surprise at the high acquisition price and others discussing the implications for the biotech sector.
Newcomers are also analyzing the performance of NUVL stock, with one post highlighting a 580% return over 5 years and another noting that the stock had a SmartScore of 9/10 before the deal, indicating that hedge funds were quietly loading up on the stock.

Generated by AI

Nuvalent

Social

Jun 10

Bullish· Jun 9

Bearish· Jun 9

Jun 9

Regulars· Nov 17

Newcomers· Jun 10

GSK secures first lung cancer approval, validating $10.6bn Nuvalent bet

GSK Lands FDA Approval for Nuvalent-Acquired Jideytro for NSCLC

GSK completes $10.6 billion acquisition of Nuvalent

Nuvalent stock hits all-time high at $123.91

GSK: Is This FTSE 100 Pharma Stock Making a Comeback?

Also Discussed

Nuvalent, Inc.

Company Information

Location

GSK secures first lung cancer approval, validating $10.6bn Nuvalent bet

GSK Lands FDA Approval for Nuvalent-Acquired Jideytro for NSCLC

GSK completes $10.6 billion acquisition of Nuvalent

Nuvalent stock hits all-time high at $123.91

GSK: Is This FTSE 100 Pharma Stock Making a Comeback?

Also Discussed

Social

Jun 10

Bullish· Jun 9

Bearish· Jun 9

Jun 9

Regulars· Nov 17

Newcomers· Jun 10